Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria

NCT ID: NCT04264234

Last Updated: 2022-03-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-13

Study Completion Date

2020-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Placenta previa cases are one of the difficult groups of patients to manage in modern obstetrics. When the literature is evaluated extensively, no clear information can be seen especially in terms of hospitalization time. Inpatient follow-up of this patients has negative effects like hospital infections in terms of the patient, workload in terms of health personnel and financial losses in terms of the country's economy. Placenta previa cases are complicated patients in which generalizations cannot be easily performed and they should be monitored at third level hospitals. In addition, care should be personalized considering the many reasons. In this study, placenta previa cases will be followed up at 28th gestational week and evaluated at 32nd week by vaginal ultrasonography and MRI and this follow-up will continue until delivery. Thus, in this study, it was aimed to determine the parameters that would allow systematic personalization of health service in this particular patient group by making risk assessment of placenta previa cases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Placenta Previa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Placenta previa cases will be followed up at 28th gestational week and evaluated at 32nd week by vaginal ultrasonography and MRI and this follow-up will continue until delivery.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placenta Previa

Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.

Group Type EXPERIMENTAL

Vaginal Ultrasonography

Intervention Type DIAGNOSTIC_TEST

Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.

Magnetic Resonance Imaging

Intervention Type DIAGNOSTIC_TEST

Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaginal Ultrasonography

Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.

Intervention Type DIAGNOSTIC_TEST

Magnetic Resonance Imaging

Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Monitoring of placenta previa
* To apply before the 28th week
* To have a low-risk second trimester screening test
* No malformation detected in the anomaly screening

Exclusion Criteria

* Multiple pregnancies
* Pregnancy complicated with preeclampsia
* Pregnancy complicated by gestational hypertension
* Pregnancy complicated by gestational diabetes mellitus
Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ege University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sabahattin Anıl Arı

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sabahattin a Arı, MD

Role: PRINCIPAL_INVESTIGATOR

Ege University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ege University Hospital

Izmir, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18-9.1/27

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pregnant Women with Placenta Previa
NCT06786156 NOT_YET_RECRUITING EARLY_PHASE1
Management of Placenta Accreta Spectrum
NCT04609527 UNKNOWN PHASE2/PHASE3